1308285-21-3 Usage
Biological Activity
sildenafil mesylate is an inhibitor of cyclic guanosine monophosphate (cgmp)-specific phosphodiesterase type 5 (pde5).pde5 is the predominant phosphodiesterase in the corpus cavernosum. the catalytic site of pde5 degrades cgmp, and pde5 inhibitors can potentiate endogenous increases in cgmp.
in vitro
sildenafil mesylate had been identified as a potent pde5 reversible and selective inhibitor. sildenafil enhanced sodium nitroprusside- or transmural electrical stimulation-induced relaxation of precontracted corpus cavernosum muscle strips in organ baths. sildenafil also increased intracellular cgmp concentrations in cultured smooth muscle cells treated with sodium nitroprusside [1].
in vivo
in anesthetized dogs, sildenafil could enhance the erectile function following pelvic nerve stimulation as measured by increased intracavernosal pressure [1].
IC 50
3.5 nm
references
[1] nehra a,colreavy f,khandheria bk,chandrasekaran k. sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. world j urol.2001 feb;19(1):40-5.[2] moore ra,edwards je,mcquay hj. sildenafil (viagra) for male erectile dysfunction: a meta-analysis of
Check Digit Verification of cas no
The CAS Registry Mumber 1308285-21-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,0,8,2,8 and 5 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1308285-21:
(9*1)+(8*3)+(7*0)+(6*8)+(5*2)+(4*8)+(3*5)+(2*2)+(1*1)=143
143 % 10 = 3
So 1308285-21-3 is a valid CAS Registry Number.
1308285-21-3Relevant articles and documents
FORMULATIONS OF PHOSPHODIESTERASE 5 INHIBITORS AND METHODS OF USE
-
, (2008/06/13)
The present invention provides compositions and delivery methods to enhance treatment for sexual dysfunction or hypofunction through the delivery of phosphodiesterase 5 inhibitors to a mammal. Phosphodiesterase inhibitors are one example of a compound class used for this indication. Examples of compounds in this class include taldalafil and vardenafil and sildenafil. Furthermore, the present invention provides compositions and delivery methods to enhance the sildenafil concentration in solution, suspension and gel formulations and methods of parenteral, intradermal, sublingual, intranasal, and buccal sildenafil delivery.
